Anlotinib improves bile duct ligature‐induced liver fibrosis in rats via antiangiogenesis regulated by VEGFR2/mTOR pathway
Sign Up to like & getrecommendations! Published in 2022 at "Drug Development Research"
DOI: 10.1002/ddr.22019
Abstract: Cholestasis is a main clinical feature of biliary atresia (BA), which leads to liver fibrosis (LF). The focus of BA treatment is preventing and slowing the progress of LF. This study reports the improvement effect… read more here.
Keywords: anlotinib; expression; effect anlotinib; phospho ... See more keywords
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02641-5
Abstract: Background Many anti-angiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy. Anlotinib has demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in third-line clinical trials. However, its roles in immune… read more here.
Keywords: anti tumor; anlotinib; lung cancer; tumor ... See more keywords
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-02869-9
Abstract: This study evaluated the efficacy and safety of anlotinib combined with programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). SCLC (n = 28) and NSCLC… read more here.
Keywords: inhibitor; treatment; anlotinib; lung cancer ... See more keywords
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.05.013
Abstract: OBJECTIVES Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret. In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival… read more here.
Keywords: placebo; quality life; anlotinib; lung cancer ... See more keywords
Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Acta Pharmacologica Sinica"
DOI: 10.1038/s41401-020-0421-7
Abstract: Anlotinib, a multitarget tyrosine kinase inhibitor, is effective as a third-line treatment against non-small cell lung cancer (NSCLC). However, acquired resistance occurs during its administration. To understand the molecular mechanisms of anlotinib resistance, we characterized… read more here.
Keywords: accessibility; anlotinib; resistance; lung cancer ... See more keywords
Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000022707
Abstract: Abstract Rationale: Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer. Patient concerns: A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month. Diagnoses: Epidermal growth… read more here.
Keywords: anlotinib; lung; lung adenocarcinoma; egfr wild ... See more keywords
Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2950
Abstract: Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is a novel multitarget tyrosine kinase inhibitor targeting VEGFR, PDGFR,… read more here.
Keywords: anlotinib; phase iib; randomized double; medullary thyroid ... See more keywords
Anlotinib Shows Potent Antileukemia Effects in B-Cell Acute Lymphocytic Leukemia through the Blockage of Angiogenic Related Pathways
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-141039
Abstract: Acute lymphoblastic leukemia (ALL) derives from the malignant transformation of lymphoid progenitor cells with ~85% being originated from B-cell progenitors (B-ALL). Despite fairly good prognoses for most pediatric B-ALL patients, the outcome is fatal in… read more here.
Keywords: cell; angiogenesis; anlotinib shows; treatment ... See more keywords
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.01562-2018
Abstract: Background Anlotinib has been demonstrated in clinical trials to be effective in prolonging the progression-free survival (PFS) and overall survival (OS) of refractory advanced nonsmall cell lung cancer (NSCLC) patients. However, the underlying molecular mechanisms… read more here.
Keywords: anti angiogenesis; nsclc patients; anlotinib; nonsmall cell ... See more keywords
Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.95
Abstract: 95 Background: The treatment option for ESCC patients (pts) progressing after chemotherapy is still uncertain. Anlotinib is a multi-target tyrosine kinase inhibitor involved in tumor angiogenesis and growth, such as vascular endothelia growth factor receptor… read more here.
Keywords: chemotherapy; anlotinib; placebo; day ... See more keywords
Safety and efficacy of hypofractionated stereotactic radiosurgery with anlotinib targeted therapy for glioblastoma at first recurrence: A preliminary report.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e14015
Abstract: e14015 Background: The optimal treatment for recurrent glioblastoma (rGBM) remains uncertain. Hypofractionated stereotactic radiotherapy (HSRT) and anti-vascular endothelial growth factor (VEGF) antibodies (e.g, bevacizumab and anlotinib) have been reported a promising survival benefit and acceptable… read more here.
Keywords: anlotinib; radiosurgery anlotinib; radiosurgery; stereotactic radiosurgery ... See more keywords